Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

CNS 2

Conditions

Brain Neoplasms 1050Glioblastoma 920Glioma 603Central Nervous System Neoplasms 436Astrocytoma 396Gliosarcoma 339Neuroblastoma 325Oligodendroglioma 255Neoplasms 181Medulloblastoma 165Breast Neoplasms 154Sarcoma 114Recurrence 108Ependymoma 105Neoplasm Metastasis 95Meningioma 91Melanoma 88Lymphoma 87Carcinoma, Non-Small-Cell Lung 87Lung Neoplasms 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Neurofibromatosis 1 79Wilms Tumor 75Osteosarcoma 69Head and Neck Neoplasms 69Ovarian Neoplasms 68Testicular Neoplasms 67Lymphoma, Non-Hodgkin 67Burkitt Lymphoma 66Familial ependymoma 63

Interventions

dexamethasone acetate 1Rituximab 1Dexamethasone 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Opsoclonus-Myoclonus Syndrome × CNS × Clear all
NCT01868269 2025-02-03

Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)

Institut Curie

Phase 3 Completed
102 enrolled
CNS

Neuroblastoma, Opsoclonus-Myoclonus Syndrome

NCT00806182 2017-05-23

OMS

National Pediatric Neuroinflammation Organization, Inc.

Completed
400 enrolled
CNS

Ataxia, Autoimmune Diseases, Neuroblastoma, Opsoclonus-Myoclonus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡